Parasite Clearance and Protection From Infection (PCPI) in Zambia
Status:
Not yet recruiting
Trial end date:
2025-02-15
Target enrollment:
Participant gender:
Summary
The Zambia PCPI study will measure the effect of the parasite genotypes associated with SP
resistance on parasite clearance and protection from infection when exposed to SP. The total
number of participants is expected to be 600 healthy between 3 to 5 years old who have no
symptoms of malaria infection of which 400 children will be assigned to the SP group and 200
to the AS group. The results of this study will allow to measure the effect of the parasite
genotypes associated with SP resistance on parasite clearance and protection from infection
when exposed to SP.
Phase:
Phase 3
Details
Lead Sponsor:
London School of Hygiene and Tropical Medicine
Treatments:
Artesunate Fanasil, pyrimethamine drug combination Pyrimethamine Sulfadoxine